To the Editor We read with interest the article from Jack et al,1 and its Editorial that shows that the prevalence of 2 neuropathologic hallmarks of Alzheimer disease (AD), β-amyloid plaques, and neurofibrillary tangles is much higher than the prevalence of 3 associated clinical manifestations: mild cognitive impairment, dementia, and probable AD.1 Notably, this asymptomatic prevalence of brain load biomarker increased by 3 times in those 85 years and older.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Montero-Odasso M, Ismail Z, Camicioli R. Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis? JAMA Neurol. Published online February 03, 2020. doi:10.1001/jamaneurol.2019.4959
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: